• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·EPIS-B.ST
Share

Episurf Medical AB Stocks

SEK 0.11Last Updated 12.06.2026

Issuer Rating

2/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

SEK 8.42M

SEK 0.11
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Episurf Medical AB (publ) is a Swedish medical technology company that specializes in the development and production of orthopedic implants and surgical instruments. Its innovative solutions are distributed across the Nordic countries, Germany, the United Kingdom, and various international markets. The company offers a range of Episealer implants designed to address localized cartilage and underlying bone defects. These include the Episealer Condyle Solo, specifically for the femoral condyles of the knee joint; the Episealer Trochlea Solo, targeting defects located behind the patella; and the Episealer Femoral Twin, which is used for more extensive, elongated defects found on the femoral condyles and within the trochlea area of the knee. For the ankle, Episurf provides the Episealer Talus, intended for osteochondral lesions of the talar dome. Beyond implants, their product line features surgical drill guides such as Epiguide, and the Epiguide MOS, specifically engineered for mosaicplasty procedures to treat deep cartilage and bone defects in the knee. Episurf also provides µiFidelity, a proprietary order management system. This platform facilitates order placement and tracking, allows for MRI scan uploads, and enables consultation of patient damage marking reports. Established in 2008 and headquartered in Stockholm, Sweden, the company adopted its current name, Episurf Medical AB (publ), in 2010, having previously operated as Diamorph Medtech AB.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of EPIS-B.ST is 0.10 and suggests 9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026